Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma

This study has been completed.
Corixa Corporation
Information provided by (Responsible Party):
Susan Knox, Stanford University Identifier:
First received: June 20, 2007
Last updated: June 19, 2014
Last verified: June 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2013
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)